银屑病患者特征与系统性治疗处方的关联:瑞士皮肤科靶向治疗注册库的语义连接图分析
结果显示共病在系统性治疗决策中起核心作用,不同治疗与年龄、疾病严重度、生活质量及共病等特征呈现多样化关联。
要点
- 共病是银屑病系统性治疗选择的核心影响因素。
- 传统系统治疗多关联于无既往系统治疗、中位生活质量及高龄。
- 生物制剂多关联于银屑病关节炎、重症及复杂治疗史。
核心结论
- 患者特征、共病、疾病严重度与银屑病系统性治疗处方之间存在多方面的关联。
- 语义图提示共病在系统性治疗使用决策中起核心作用。
研究设计与样本
- 共纳入549例患者,平均年龄46.7±14.7岁,采用语义图分析捕捉变量间最佳关联。
主要发现
- 维A酸类和甲氨蝶呤与无既往系统治疗、治疗开始时中等生活质量及年龄≥60岁相关。
- 富马酸衍生物与轻度银屑病(PASI<10)及长病程(≥20年)相关。
- 环孢素和PUVA/UVB与更严重病情相关,包括生活质量受损、住院和无法工作。
- 英夫利西单抗和阿达木单抗与银屑病关节炎、严重病情及其他共病(包括慢性肝或肾病和结核)相关。
- 依那西普、乌司奴单抗和苏金单抗与复杂既往系统治疗史、中度病情、超重和大学教育相关。
临床怎么用
- 临床选择银屑病系统性治疗时应综合评估患者共病、疾病严重度及既往治疗史。
- 对于有银屑病关节炎或严重共病的患者,生物制剂选择需考虑相关关联模式。
局限性
- 本研究为回顾性分析,语义图关联不代表因果关系。
- 未来研究需进一步探究数据中出现的特定关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several treatment options are currently available for the treatment of psoriasis. OBJECTIVE: To explore the main associations between patients' characteristics and systemic treatments prescribed for psoriasis in a large group of patients observed in real-life clinical practice. METHODS: This was a retrospective analysis of baseline data collected within the Swiss Dermatology Network for Targeted Therapies registry in Switzerland between March 2011 and December 2017. Semantic map analysis was used in order to capture the best associations between variables taking into account other covariates in the system. RESULTS: A total of 549 patients (mean age 46.7 ± 14.7 years) were included in the analysis. Conventional therapies such as retinoids and methotrexate were associated with no previous systemic therapies for psoriasis, a moderate quality of life (QoL) at therapy onset and older age (≥60 years). Fumaric acid derivatives were associated with mild psoriasis (psoriasis area severity index < 10) and long disease duration (≥20 years). On the other side, cyclosporine and psoralen and ultraviolet A/ultraviolet B treatments were linked to a more severe condition, including impaired QoL, hospitalization and inability to work. Regarding biological therapies, both infliximab and adalimumab were connected to the presence of psoriatic arthritis, severe disease condition and other comorbidities, including chronic liver or kidney diseases and tuberculosis. Etanercept, ustekinumab and secukinumab were all connected to a complex history of previous systemic treatments for psoriasis, moderate disease condition, overweight and university education. CONCLUSIONS: The analysis shows multifaceted associations between patients' characteristics, comorbidities, disease severity and systemic treatments prescribed for psoriasis. In particular, our semantic map indicates that comorbidities play a central role in decision-making of systemic treatments usage for psoriasis. Future studies should further investigate specific connections emerging from our data.
引用
- Cazzaniga S, Anzengruber F, Augustin M, et al. Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. J Eur Acad Dermatol Venereol. 2019. PMID: 31562785. doi:10.1111/jdv.15983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。